Riskpilot← Back to searchSign inGet full accessMedivak OY
OYDissolvedY-tunnus 2795213-2Majajärvenrinne 18Medical specialists activities · NACE 8622Est. 20161 employees
Revenue 2024
EUR 370K
-94% vs 2023
EBITDA margin
71.9%
-99% vs 2023
Equity ratio
97.8%
Financial strength
Net profit 2024
EUR 210K
-99% vs 2023
| Revenue | EUR 370K | -94% |
| EBITDA | EUR 266K | -99% |
| Net profit | EUR 210K | -99% |
| Total assets | EUR 1M | +6% |
| Equity | EUR 981K | +17% |
| Employees | 1 | — |
Legal name
Medivak OY
Y-tunnus number
2795213-2
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
16. marraskuuta 2016
Share capital
EUR 2 500
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Lääkäripalvelut, asiantuntijapalvelut, välitystoiminta, vakuutusvälitystoiminta, rakennusurakointi, suunnittelu- ja konsultointipalvelut. Yhtiö voi toimintaansa varten ostaa, myydä ja vuokrata kiinteää omaisuutta. Lisäksi yhtiö voi omistaa ja hallita osakkeita, osakehuonesitoja ja muita arvopapereita. Yhtiö voi lisäksi harjoittaa kaikkea laillista liiketoimintaa.
Address
Majajärvenrinne 18
Phone
+358505559471
Email
olli-pekka.kangasniemi@outlook.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 277 | 286 | 305 | 5 788 | 370 |
| Staff expenses | −4 | −5 | −4 | 2 | −4 |
| EBITDA | 215 | 216 | 228 | 23 034 | 266 |
| Depreciation & amort. | — | — | — | −0 | −0 |
| EBIT | 215 | 216 | 228 | 23 034 | 266 |
| Net financials | −1 | −2 | −5 | −8 | −3 |
| Profit before tax | 214 | 215 | 224 | 22 250 | 263 |
| Tax | 43 | 43 | 45 | 45 | 53 |
| Net profit | 171 | 171 | 179 | 17 756 | 210 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 503 | 828 | 878 | 950 | 1 004 |
| Equity | 461 | 586 | 718 | 839 | 981 |
| Long-term debt | 5 | 140 | 60 | 0 | 0 |
| Short-term debt | 36 | 102 | 100 | 112 | 22 |
| Total debt | 41 | 242 | 160 | 112 | 22 |
EBITDA margin
71.9%
This company
15.8%
Market median
+355% vs market
20202024
Equity ratio
97.8%
This company
38.2%
Market median
+156% vs market
20202024
Return on equity
21.4%
This company
18.4%
Market median
+16% vs market
20202024
Net profit margin
56.7%
This company
8.1%
Market median
+600% vs market
20202024
Asset turnover
0.37×
This company
1.12×
Market median
-67% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
LS Deputy Member | Deputy Member | 2016 |
OK Chief Executive Officer | Chief Executive Officer | 2016 |
AK Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2016 |
SJ Audit | Audit | 2025 |
| Former (1) | ||
TJ | Audit | 2022 – 2023 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medivak OY also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tapio Johannes Raappana | Audit | 0 companies |
| Lauri Sakari Vappula | Deputy Member | 0 companies |
| Olli-Pekka Kangasniemi | Chief Executive Officer | 0 companies |
| Anna-Kaisa Kangasniemi | Deputy Chief Executive Officer | 0 companies |
| Siina Jasmin Raiskio | Audit | 0 companies |